

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
23 January 2025 (23.01.2025)



(10) International Publication Number
WO 2025/017103 A1

(51) International Patent Classification:

C07D 209/42 (2006.01)	C07D 498/04 (2006.01)
C07D 401/06 (2006.01)	A61P 25/28 (2006.01)
C07D 401/12 (2006.01)	A61K 31/404 (2006.01)
C07D 403/06 (2006.01)	A61K 31/4965 (2006.01)
C07D 403/12 (2006.01)	A61K 31/4985 (2006.01)
C07D 403/14 (2006.01)	A61P 5/00 (2006.01)
C07D 405/06 (2006.01)	A61P 9/00 (2006.01)
C07D 471/08 (2006.01)	A61P 25/00 (2006.01)
C07D 471/10 (2006.01)	A61P 35/00 (2006.01)
C07D 487/04 (2006.01)	A61P 37/00 (2006.01)
C07D 487/08 (2006.01)	C07D 498/10 (2006.01)
C07D 487/10 (2006.01)	

RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/EP2024/070337

(22) International Filing Date:

18 July 2024 (18.07.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

23186193.1	18 July 2023 (18.07.2023)	EP
23191955.6	17 August 2023 (17.08.2023)	EP
23205179.7	23 October 2023 (23.10.2023)	EP
24177383.7	22 May 2024 (22.05.2024)	EP

(71) Applicant: MUNA THERAPEUTICS APS [DK/DK];
Nordre Fasanvej 215, 2000 Frederiksberg (DK).

(72) Inventors: BUSCH-PETERSEN, Jakob; c/o Muna Therapeutics ApS, Nordre Fasanvej 215, 2200 Copenhagen N (DK). ANDERSEN, Kim; c/o Muna Therapeutics ApS, Nordre Fasanvej 215, 2200 Copenhagen N (DK). WHIT-LOCK, Gavin; c/o Sandexis Medicinal Chemistry Ltd, Innovation House, Discovery Park, Ramsgate Road, Sandwich, Kent CT13 9FF (GB). JOKINEN, Elmeri Matias; c/o Aurlide Ltd., DataCity Werstas, Lemminkäisenkatu 14-18 A3, 20520 Turku (FI).

(74) Agent: HØIBERG P/S; Adelgade 12, 1304 Copenhagen K (DK).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))
— in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: KVL3 POTASSIUM CHANNEL ANTAGONISTS

(57) Abstract: The present invention relates to Kv1.3 potassium channel antagonists and their use in the treatment and management of inflammatory diseases, including neuroinflammatory diseases.

WO 2025/017103 A1